Dapagliflozin in Patients With Atrial Fibrillation (DAPA-AF) (NCT05174052)
Dapagliflozin in Patients With Atrial Fibrillation
🩺 Plain-English Summary (8th-Grade Level)
The study will investigate the effect of Dapagliflozin on atrial fibrillation (AF) burden. AF burden will be defined as the percent of time spent in AF over a 2-week period, assessed by noninvasive continuous heart rhythm monitoring at baseline and at 3 months, quality of life (QOL) and validated echocardiographic indices of atrial myopathy. This knowledge will enable us to study the therapeutic potential of SGLT2i as a novel adjunct treatment for patients with DM and AF. Patients with paroxysmal AF (AF that terminates spontaneously or with intervention within seven days of onset) and DM and randomize them to Dapagliflozin or placebo. Continuous heart rhythm monitoring patch for AF burden will be used, measure of QOL with the help of AF Effect on Quality-of-life survey and perform an echocardiogram with measurement of left atrial volume index, left atrial strain and atrial tissue dopplers. All measurements will be performed at baseline and at study completion. The central hypothesis is that SGLT2i will lead to reduced AF burden that will translate into improvement in QOL, and the underlying mechanism is improvement in atrial myopathy.
Who can join: Review the eligibility criteria below.
Location: University of Oklahoma Health Sciences Center — Oklahoma City, Oklahoma
Age range: 18 Years to 85 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- University of Oklahoma Health Sciences Center — Oklahoma City, Oklahoma
📞 Contact the Study Coordinator
Phone: (405) 271-8001
Email: Aurora-Vera@ouhsc.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Diabetes Mellitus
- The REST Study for CGM Use in Older Adults With Insulin-treated Diabetes — Boston, Massachusetts
- Oral Anti Diabetic Agents in the Hospital — Atlanta, Georgia
- Full Plate Living Nutrition Education Program — Madison, Wisconsin
- Evaluation of Arts-Based Storytelling Program in Adolescents With Diabetes — San Francisco, California
- Impact of Per Oral Pyloromyotomy (POP) on Glycemic Control in Diabetes — Cleveland, Ohio
- Repeat BCG Vaccinations for the Treatment of New Onset Type 1 Diabetes in Children Age 8-<18 Years — Charlestown, Massachusetts
Explore by condition: All Diabetes Mellitus clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.